As the use of teprotumumab for thyroid eye disease (TED) becomes more prolific, there remains a scarcity of literature regarding the associated side effects and adverse events of teprotumumab use. The authors present a single-center retrospective, observational case review of TED patients who ...
Common side effects include nausea, diarrhea, muscle spasms, hearing impairment, dysgeusia, headaches, dry skin, infusion reactions, alopecia, paresthesia, weight loss, and hyperglycemia. Other possible serious effects reported include optic neuropathy, encephalopathy, urinary retention, inflammatory bowel ...
The most common side effects were muscle cramps (42%), hyperglycemia (19%), muffled hearing (11.5%), tinnitus (11.5%), and non-bloody diarrhea (11.5%). Fatigue, paresthesia, headache, nausea, hair loss, and dizziness were also reported. This study shows that teprotumumab treatment ...
aPathogenic autoantibodies stimulating the orbital fibroblasts resulting in production of hyaluronan and giving rise to symptoms of thyroid eye disease.bTeprotumumab (an IGF-1R antagonist) blocks the stimulatory effects of pathogenic autoantibodies on the orbital fibroblasts TSI thyroid stimulating immunoglo...
Current therapy of active TAO consists most frequently of glucocorticoid steroids, orbital radiation, or B-cell depletion; all of which are associated with substantial side effects. Teprotumumab (Tepezza) is a human monoclonal antibody against the insulin-like growth factor type I receptor (IGF-...
DRUG side effectsTHYROIDITISGRAVES' diseaseHYPOTHYROIDISMDERMATOLOGYPretibial myxedema, more generally thyroid dermopathy, results from mucopolysaccharide accumulation in the dermis, typically between the knee and dorsal foot. Thyroid dermopathy presents in Graves disease, but can occur in Hashimoto...
Side effects were experienced by 85% of patients on teprotumumab. Hearing loss symptoms were reported in 10% of patients and were reported to be reversible upon stopping the drug. Objective: To explore the incidence of hearing loss symptoms and sensorineural hearing loss in patients treated ...
The authors present the first reported case of successful teprotumumab treatment in an adolescent patient, describing outcomes and proposing a mechanism for her transient side effects.doi:10.1097/IOP.0000000000002588Nicholas,RadulovichAlexandra,Van Brummen...
Spectral-domain optical coherence tomographyTeprotumumabThyroid eye diseasePrior studies have demonstrated the potential side effects of insulin-like growth factor-1 (IGF-1) inhibition for thyroid eye disease (TED) including hearing loss. In this study, we assessed changes in functional vision ...
Multiple studies have shown significant positive results in disease modulation, as well as limited side effects.Brooke E. BockludSchool of Medicine, Louisiana State University Health Sciences Center, Shreveport, USAWaddih FakhreSchool of Medicine, Louisiana State University Health Sc...